Eyevi

Eyevi is an antioxidant micronutrient combination (an AREDS2-type formulation) primarily used as a nutritional supplement to support eye health. Its main evidence-based use is:

• Reducing the risk of progression of age-related macular degeneration (AMD): Based on the AREDS2 (Age-Related Eye Disease Study 2) clinical trial, this combination is guideline-supported for patients with intermediate AMD (or advanced AMD in one eye) to reduce the risk of progression to advanced AMD and associated vision loss. It is not indicated as a treatment for early AMD or as a cure for existing vision loss.
• General ocular antioxidant/nutritional support: Eyevi is also marketed more broadly as an advanced antioxidant supplement providing nutritional support against oxidative stress in the eye (e.g., in patients with low dietary intake of antioxidants), though this general supportive use has weaker evidence than the specific AMD-progression indication.

Eyevi is a supportive/preventive supplement, not a treatment for cataracts, glaucoma, or acute eye disease, and does not restore vision already lost.

Each capsule/tablet of Vitamin C, Vitamin E, Lutein, Copper and Zinc typically contains a combination of:

• Vitamin C (ascorbic acid) — approximately 500 mg
• Vitamin E (as mixed tocopherols/tocopheryl acetate) — approximately 400 IU
• Lutein — approximately 10 mg
• Zinc (as zinc oxide) — approximately 25–40 mg elemental zinc
• Copper (as cupric oxide) — approximately 1–2 mg

Exact strengths vary slightly by brand/manufacturer; refer to the specific product label for the precise composition of the formulation being dispensed.

Eyevi is a fixed-dose combination nutritional supplement modeled on the AREDS2 (Age-Related Eye Disease Study 2) formula, a large multicenter clinical trial sponsored by the US National Eye Institute. The combination pairs antioxidant vitamins (C and E) with the macular carotenoid lutein and the trace minerals zinc and copper.

Copper is included specifically to offset the copper deficiency (and associated anemia) that can occur with long-term high-dose zinc supplementation. This formulation is available as an oral capsule/tablet and is used as an adjunct to a healthy diet, not as a replacement for regular ophthalmologic care.

Ophthalmic nutritional supplement / Antioxidant vitamin-mineral combination — Eyevi belongs to the class of multivitamin and mineral supplements used for ocular antioxidant support.

Vitamin C, Vitamin E, Lutein, Copper and Zinc works through the combined antioxidant and micronutrient roles of its components:

• Vitamin C: A water-soluble antioxidant that concentrates in the aqueous humor and lens, scavenging free radicals and reducing oxidative damage linked to cataract and AMD progression.
• Vitamin E: A lipid-soluble antioxidant that protects cell membranes, including retinal photoreceptor membranes, from lipid peroxidation.
• Lutein: A xanthophyll carotenoid that is selectively concentrated in the macula (as macular pigment), where it filters high-energy blue light and neutralizes reactive oxygen species, protecting photoreceptors and the retinal pigment epithelium.
• Zinc: A cofactor for numerous retinal enzymes (including those involved in retinol metabolism) and supports overall retinal metabolic function.
• Copper: Included to prevent the zinc-induced copper deficiency that can occur with sustained high-dose zinc intake; copper is itself a cofactor for antioxidant enzymes such as superoxide dismutase.

Together, these components are thought to reduce oxidative stress in the retina and macula, which is implicated in the pathogenesis of age-related macular degeneration.

Eyevi is taken by mouth, ideally with food, to enhance absorption of the fat-soluble components (vitamin E and lutein) and to minimize gastrointestinal irritation. It should be swallowed whole with a glass of water.

• Anticoagulants/antiplatelet drugs (e.g., warfarin, heparin, aspirin): The vitamin E component of Eyevi, particularly at higher doses, can antagonize vitamin K-dependent clotting factors and increase bleeding risk; monitor for signs of bleeding and INR (where applicable) in patients on anticoagulant therapy.
• Other vitamin E or zinc supplements/multivitamins: Concomitant use of additional high-dose vitamin E or zinc products with Eyevi should be avoided to prevent cumulative toxicity; review a patient's full supplement list before initiating therapy.
• Tetracycline and quinolone antibiotics: The zinc content of Eyevi can chelate and reduce the absorption of these antibiotics if taken together; separate administration by at least 2 hours.
• Penicillamine: Zinc may reduce the efficacy of penicillamine; avoid co-administration where possible.

Eyevi is generally well tolerated. Reported adverse effects include:

• Gastrointestinal disturbances — nausea, diarrhea, abdominal cramps (mainly related to high-dose vitamin C)
• Mild fatigue or weakness (associated with high-dose vitamin E)
• Yellowing/staining of urine (harmless, related to riboflavin/vitamin content in some formulations)
• Unpleasant taste or mild nausea (related to zinc content), especially if taken on an empty stomach

These effects are usually mild and self-limiting, and may be reduced by taking the supplement with food.

Eyevi should be used during pregnancy and breastfeeding only if clearly needed and after consultation with a physician, as it should be weighed against the mother's overall vitamin/mineral intake from prenatal vitamins and diet to avoid exceeding safe upper limits (particularly for vitamin E and zinc). There is no established indication for AMD risk reduction in pregnant or lactating women, as AMD occurs in an older population; use in this group would typically be for general nutritional purposes only, under medical supervision.

• Zinc/copper balance: Eyevi already contains copper to offset zinc-induced copper deficiency; patients should not take additional high-dose zinc supplements separately, as this can still cause copper deficiency, anemia, and neurological effects over time.
• Bleeding risk: Use with caution in patients on anticoagulant or antiplatelet therapy due to the vitamin E component (see Interactions).
• Avoid duplicate supplementation: Patients should avoid taking additional multivitamins or eye supplements containing high-dose vitamin E or zinc concurrently with Eyevi to prevent cumulative overdose.
• Hyperoxaluria/kidney stone history: Use vitamin C-containing products like Eyevi cautiously in patients with a history of oxalate kidney stones, as high-dose vitamin C can increase urinary oxalate excretion.
• Smokers (historical AREDS formula note): Some earlier AREDS-type formulas containing beta-carotene were associated with increased lung cancer risk in smokers; the AREDS2-type formulation reflected in Eyevi uses lutein instead of beta-carotene and does not carry this specific warning, but smokers should still confirm formulation contents with their physician/pharmacist.

Overdose of Eyevi may present as severe gastrointestinal upset (nausea, vomiting, diarrhea), and with chronic excessive intake, signs of zinc toxicity (copper deficiency, anemia, impaired immune function) or vitamin toxicity. If an overdose is suspected, seek immediate medical attention or contact a poison control center; do not attempt to manage a suspected overdose at home without professional guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Eyevi is specifically formulated for the age group most affected by AMD (typically 50 years and older) and is generally well tolerated in this population; no specific dose adjustment beyond standard dosing is established.

Renal impairment: Use with caution; reduced clearance of zinc and vitamin C metabolites may occur. Consult a physician before use.

Hepatic impairment: No specific dose adjustment is established; use with general caution and physician guidance.

Smokers: Should use only lutein-based (not beta-carotene-based) formulations such as Eyevi, and should confirm this with their pharmacist, given a historical lung cancer signal associated with beta-carotene-containing eye vitamin formulas in smokers.

Eyevi is typically used long-term (often for years, as demonstrated in the 5-year AREDS2 trial) under ophthalmologic supervision for AMD progression risk reduction, with periodic eye examinations to monitor disease status. Duration for general nutritional support should be guided by a physician based on individual need.

Multivitamin and mineral supplement; ophthalmic antioxidant combination

Vitamin C, Vitamin E, Lutein, Copper and Zinc combines antioxidant vitamins (C and E), the macular carotenoid lutein, and the trace minerals zinc and copper to reduce oxidative stress in the retina and macula, a process implicated in the development and progression of age-related macular degeneration; copper is included to prevent zinc-induced copper deficiency.

Eyevi is not indicated for use in children, as age-related macular degeneration is a condition of older adults. Safety and efficacy of this specific combination have not been established in the pediatric population, and it should not be given to children except under specific medical/nutritional guidance unrelated to its AMD indication.